Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Behavioral Medicine
Published in: Annals of Behavioral Medicine 3/2014

01-12-2014 | Original Article

Approaches for Informing Optimal Dose of Behavioral Interventions

Authors: Corrine I. Voils, PhD, Heather A. King, PhD, Matthew L. Maciejewski, PhD, Kelli D. Allen, PhD, William S. Yancy Jr., MD, MHS, Jonathan A. Shaffer, PhD

Published in: Annals of Behavioral Medicine | Issue 3/2014

Login to get access

Abstract

Background

There is little guidance about to how select dose parameter values when designing behavioral interventions.

Purpose

The purpose of this study is to present approaches to inform intervention duration, frequency, and amount when (1) the investigator has no a priori expectation and is seeking a descriptive approach for identifying and narrowing the universe of dose values or (2) the investigator has an a priori expectation and is seeking validation of this expectation using an inferential approach.

Methods

Strengths and weaknesses of various approaches are described and illustrated with examples.

Results

Descriptive approaches include retrospective analysis of data from randomized trials, assessment of perceived optimal dose via prospective surveys or interviews of key stakeholders, and assessment of target patient behavior via prospective, longitudinal, observational studies. Inferential approaches include nonrandomized, early-phase trials and randomized designs.

Conclusions

By utilizing these approaches, researchers may more efficiently apply resources to identify the optimal values of dose parameters for behavioral interventions.
Literature
1.
Voils CI, Chang YK, Crandell JL, et al.: Informing the dosing of interventions in randomized trials. Contemp Clin Trials. 2012.
2.
3.
Lilienfeld SO. Psychological treatments that cause harm. Perspect Psychol Sci. 2007; 2: 53-70.CrossRef
4.
Collins LM, Baker TB, Mermelstein RJ, et al. The multiphase optimization strategy for engineering effective tobacco use interventions. Ann Behav Med. 2011; 41: 208-226.PubMedCentralPubMedCrossRef
5.
Collins LM, Murphy SA, Strecher V. The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): New methods for more potent eHealth interventions. Am J Prev Med. 2007; 32: S112-S118.PubMedCentralPubMedCrossRef
6.
Waters LA, Winkler EA, Reeves MM, Fjeldsoe BS, Eakin EG. The impact of behavioural screening on intervention outcomes in a randomised, controlled multiple behaviour intervention trial. International Journal of Behavioral Nutrition & Physical Activity. 2011; 8: 24.CrossRef
7.
Dickens C, Cherrington A, Adeyemi I, et al.: Characteristics of psychological interventions that improve depression in people with coronary heart disease: A systematic review and meta-regression. Psychomsomatic Medicine. 2013, epub ahead of print.
8.
Moyer VA. Screening for and management of obesity in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012; 157: 373-378.PubMed
9.
10.
Schünemann HJ, Oxman AD, Vist GE, et al.: Chapter 12: Interpreting results and drawing conclusions. In J. P. T. Higgins and S. Green (eds), Cochrane Handbook for Systematic Reviews of Interventions (Vol. 5.1.0), 2011.
11.
Krumholz HM, Selby JV. Seeing through the eyes of patients: The patient-centered outcomes research institute funding announcements. Ann Intern Med. 2012; 157: 446-447.PubMed
12.
Yancy W Jr, Westman E, McDuffie J, et al. A randomized trial of a low-carbohydrate, ketogenic diet versus orlistat plus a low-fat diet for weight loss. Arch Intern Med. 2010; 170: 136-145.PubMedCrossRef
13.
Willis G. Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks: Sage; 2005.
14.
Ram N, Gerstorf D. Time-structured and net intraindividual variability: Tools for examining the development of dynamic characteristics and processes. Psychol Aging. 2009; 24: 778-791.PubMedCentralPubMedCrossRef
15.
Nesselroade JR. The warp and woof of the developmental fabric. In: Downs R, Liben L, Palermo D, eds. Visions of development, the environment, and aesthetics: The legacy of Joachim F. Wohlwil. Hillsdale, NJ: Erlbaum; 1991: 213-240.
16.
Sliwinski M. Measurement burse designs for social health research. Soc Personal Psychol Compass. 2008; 2: 245-261.CrossRef
17.
Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: Adherence assessment or intervention? HIV Clin Trials. 2002; 3: 45-51.PubMedCrossRef
18.
van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: A retrospective cohort study. Hypertension. 2011; 58: 573-578.PubMedCrossRef
19.
Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. Journal of Acquired Immune Deficiency Syndrome. 2006; 43(Suppl 1): S79-S87.CrossRef
20.
Garrett-Mayer E. The continual reassessment method for dose-finding studies: A tutorial. Clinical Trials. 2006; 3: 57-71.PubMedCrossRef
21.
22.
Cheung Y, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000; 56: 1177-1182.PubMedCrossRef
23.
Hu C, Cheung Y. On the efficiency of nonparametric variance estimation in sequential dose-finding. Journal of Statistical Planning and Inference. 2012; 143: 593-602.CrossRef
24.
Chen Z, Tighiouart M, Kowalski J. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer phase I clinical trials. Contemporary Clinical Trials. 2012; 33: 949-959.PubMedCentralPubMedCrossRef
25.
Thall P, Cook J. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004; 60: 684-693.PubMedCrossRef
26.
Toseland R, Blachard C, McCallion P. A problem solving intervetnion for caregivers of cancer patients. Soc Sci Med. 1995; 40: 517-528.PubMedCrossRef
27.
Spertus J, Peterson E, Conard M, et al. Monitoring clinical changes in patients with heart failure: A comparison of methods. Am Heart J. 2005; 150: 707-715.PubMedCrossRef
28.
Howard KI, Kopta SM, Krause MS, Orlinsky DE. The dose-effect relationship in psychotherapy. Am Psychol. 1986; 41: 159-164.PubMedCrossRef
29.
Fisher R. The arrangement fo field experiments. Journal of the Ministry of Agriculture of Great Britain. 1926; 33: 503-513.
30.
Collins LM, Dziak JJ, Li R. Design of experiments with multiple independent variables: A resource managemetn perspective on complete and reduced factorial designs. Psychol Methods. 2009; 14: 202-224.PubMedCentralPubMedCrossRef
31.
Gabler N, Duan N, Vohra S, Kravitz R. N-of-1 trials in the medical literature: A systematic review. Med Care. 2011; 49: 761-768.PubMedCrossRef
32.
33.
Guyatt GH, Jaeschke R, McGinn T. N-of-1 randomized controlled trials: Study design. In: Guyatt GH, Rennie D, Meade M, Cook D, eds. Users’ guides to the medical literature. New York: McGraw Hill Medical; 2008: 179-192.
34.
Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A “SMART” design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012; 8: 21-48.PubMedCrossRef
35.
36.
Moyers T, Martin T, Manuel J, Hendrickson S, Miller W. Assessing competence in the use of motivational interviewing. J Subst Abus Treat. 2005; 28: 19-26.CrossRef
37.
38.
Lorencatto F, West R, Christopherson C, Michie S. Assessing fidelity of delivery of smoking cessation behavioural support in practice. Implement Sci. 2013; 8: 40.PubMedCentralPubMedCrossRef
39.
Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions. Health Psychol. 2008; 27: 379-387.PubMedCrossRef
40.
Volpp KG, Gurmankin Levy A, Asch DA, et al. A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol Biomark Prev. 2006; 15: 12-18.CrossRef
41.
Burns RJ, Donovan AS, Ackermann RT, et al. A theoretically grounded systematic review of material incentives for weight loss: Implications for interventions. Ann Behav Med. 2012; 44: 375-388.PubMedCrossRef
Metadata
Title
Approaches for Informing Optimal Dose of Behavioral Interventions
Authors
Corrine I. Voils, PhD
Heather A. King, PhD
Matthew L. Maciejewski, PhD
Kelli D. Allen, PhD
William S. Yancy Jr., MD, MHS
Jonathan A. Shaffer, PhD
Publication date
01-12-2014
Publisher
Springer US
Published in
Annals of Behavioral Medicine / Issue 3/2014
Print ISSN: 0883-6612
Electronic ISSN: 1532-4796
DOI
https://doi.org/10.1007/s12160-014-9618-7

Other articles of this Issue 3/2014

Annals of Behavioral Medicine 3/2014 Go to the issue

Original Article

Does Electronic Monitoring Influence Adherence to Medication? Randomized Controlled Trial of Measurement Reactivity

Original Article

Randomized Study of Placebo and Framing Information in Direct-to-Consumer Print Advertisements for Prescription Drugs

Original Article

Fear-Avoidance, Pain Acceptance and Adjustment to Chronic Pain: A Cross-Sectional Study on a Sample of 686 Patients with Chronic Spinal Pain

Original Article

Effects of a Multiple Health Behavior Change Intervention for Colorectal Cancer Survivors on Psychosocial Outcomes and Quality of Life: a Randomized Controlled Trial

Original Article

High Trait Rumination Is Associated with Blunted Nighttime Diastolic Blood Pressure Dipping

Original Article

Testing Negative Means I’m Lucky, Making Good Choices, or Immune: Diverse Reactions to HIV Test Results are Associated with Risk Behaviors